Gastrointestinal Cancer

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab with chemotherapy for advanced gastric or GEJ adenocarcinoma.

177Lu-edotreotide prolonged PFS vs everolimus in patients with inoperable, progressive, grade 1 or 2 gastroenteropancreatic neuroendocrine tumors.

The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Camrelizumab plus Nab-POF was associated with high rates of conversion to R0 resection and high 3-year survival rates in gastric and GEJ adenocarcinoma.

The phase 2 NeoCaCRT trial evaluating neoadjuvant SCRT plus cadonilimab/chemotherapy met its primary end point of pCR rate in locally advanced rectal cancer.

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

Relapse-free survival rates were not improved when chemoradiation was added to chemotherapy in resected gallbladder cancer, according to data from the ACCELERATE trial.

Certepetide plus gemcitabine and nab-paclitaxel showed antitumor activity despite failing to improve PFS vs chemotherapy alone in untreated metastatic pancreatic cancer.

TACE with camrelizumab and rivoceranib elicited a clinically meaningful PFS improvement among patients with unresectable HCC.

A subgroup analysis of the CABINET trial showed that cabozantinib extended PFS vs placebo in extrapancreatic NETs with a primary tumor arising in the GI tract.

OS was not improved with pembrolizumab plus lenvatinib and chemotherapy vs chemotherapy alone in advanced HER2-negative gastroesophageal adenocarcinoma.

Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.

Tislelizumab plus irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin showcased encouraging efficacy and manageable safety in gastric/GEJ cancer.

Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.

Evorpacept plus TRP produced superior ORR, DOR, and PFS outcomes vs TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer.

Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.

Everolimus plus lanreotide demonstrated an improved PFS compared with everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.

E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.

ELC-100 has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic neuroendocrine tumors.

An orphan medicinal product designation was granted to elraglusib by the EMA for patients with advanced pancreatic ductal adenocarcinoma.

Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.

China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.

Aparna Parikh, MD, discusses the first-line treatment field for patients with hepatocellular carcinoma, highlighting notable immunotherapy options.

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.